SCHEMBL3750336

SCHEMBL3750336

COC(=O)c1ccc2c(c1)c(C)c(-c1ccccn1)n2C1CCCC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RPS6KB1 P23443 1/20 0.42
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42
GABRA4 P48169 1/20 0.42
GABRE P78334 1/20 0.42
GABRA6 Q16445 1/20 0.42
GABRG1 Q8N1C3 1/20 0.42
GABRG3 Q99928 1/20 0.42
GABRQ Q9UN88 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 3/20 0.40
ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5141799 0.90 MEN1 (0.52) KDM4EALDH1A1OPRM1OPRD1OPRK1
SCHEMBL3744484 0.89 L3MBTL1 (0.49) KDM4ESMN1; SMN2MEN1KMT2AEGFR
SCHEMBL12051162 0.84 KCNH2 (0.53) RPS6KB1GABRPGABRDGABRA1GABRB1
SCHEMBL3752695 0.80 RPS6KB1 (0.49) RPS6KB1GABRPGABRDGABRA1GABRB1
SCHEMBL12051172 0.79 RPS6KB1 (0.48) RPS6KB1GABRPGABRDGABRA1GABRB1
SCHEMBL3747486 0.77 ALDH1A1 (0.47) RPS6KB1GABRPGABRDGABRA1GABRB1
SCHEMBL12051166 0.76 ALDH1A1 (0.49) RPS6KB1GABRPGABRDGABRA1GABRB1
SCHEMBL30158822 0.76 MEN1 (0.56) RPS6KB1KDM4EMEN1KMT2ANPC1
SCHEMBL28267709 0.76 ALDH1A1 (0.51) RPS6KB1GABRPGABRDGABRA1GABRB1
SCHEMBL4809086 0.74 CYP3A4 (0.59) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838537-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-23 US disclosed
US-7838537-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-23 US disclosed
US-7838537-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-11-23 US disclosed
EP-1587585-B1 ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES BOEHRINGER INGELHEIM INT (DE) 2008-10-15 EP disclosed
EP-1587585-B1 ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES BOEHRINGER INGELHEIM INT (DE) 2008-10-15 EP disclosed
US-20080119490-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-22 US disclosed
US-20080119490-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-22 US disclosed
US-20080119490-A1 Viral Polymerase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-22 US disclosed
US-7323470-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-01-29 US disclosed
US-7323470-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-01-29 US disclosed
US-7098231-B2 Viral polymerase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-08-29 US disclosed
EP-1587585-A1 ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES Boehringer Ingelheim International GmbH (DE) 2005-10-26 EP disclosed
US-20040186125-A1 E.g , 3-cyclohexyl-2-furan-3-yl-1Hindole-5-carboxylic acid; hepatitis C viricides that target RNA dependent RNA polymerases (Ns5B) in mammals, an enzyme essential to viral replication; used in conjunction with an mmunomodulatory agent, such as beta -, delta - gamma -, and omega -interferon BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-09-23 US disclosed
WO-2004064925-A1 VIRAL POLYMERASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119490-A1 Viral Polymerase Inhibitors POLM, POLR2H, POLR2A RPS6KB1 572/4885GABRP 1564/4885GABRD 4378/4885
US-20040186125-A1 E.g , 3-cyclohexyl-2-furan-3-yl-1Hindole-5-carboxylic acid; hepatitis C viricides that target RNA dependent RNA polymerases (Ns5B) in mammals, an enzyme essential to viral replication; used in conjunction with an mmunomodulatory agent, such as beta -, delta - gamma -, and omega -interferon IFNAR1, IFNG, EIF2AK2 RPS6KB1 1395/4885GABRP 1119/4885GABRD 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.